Spero Therapeutics Inc. (SPRO) Prices 5.5M Share IPO at $14/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Spero Therapeutics Announces Pricing of Initial Public Offering
November 1, 2017 6:00 PM EDTCAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. Spero Therapeutics, Inc.s shares are expected to begin trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol SPRO. All of the shares are being offered by Spero Therapeutics, Inc.  In addition, Spero Therapeutics,... More
